<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39339957</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity of an Inactivated COVID-19 Vaccine in People Living with HIV in Guangxi, China: A Prospective Cohort Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1481</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091481</ELocationID><Abstract><AbstractText>The inactivated COVID-19 vaccine has demonstrated high efficacy in the general population through extensive clinical and real-world studies. However, its effectiveness in immunocompromised individuals, particularly those living with HIV (PLWH), remains limited. In this study, 20 PLWH and 15 HIV-seronegative individuals were recruited to evaluate the immunogenicity of an inactivated COVID-19 vaccine in PLWH through a prospective cohort study. The median age of the 20 PLWH and 15 HIV-seronegative individuals was 42 years and 31 years, respectively. Of the PLWH, nine had been on ART for over five years. The median anti-SARS-CoV-2 S-RBD IgG antibody level on d<sub>224</sub> was higher than that on d<sub>42</sub> (8188.7 ng/mL vs. 3200.9 ng/mL, <i>P</i> &lt; 0.05). Following COVID-19 infection, the antibody level increased to 29,872.5 ng/mL on d<sub>re+90</sub>, 12.19 times higher than that on d<sub>300</sub>. Compared with HIV-seronegative individuals, the antibody level in PLWH was lower on d<sub>210</sub> (183.3 ng/mL vs. 509.3 ng/mL, <i>P</i> &lt; 0.01), while there was no difference after d<sub>224</sub>. The symptoms of COVID-19 infection in PLWH were comparable to those in HIV-seronegative individuals. In this study, the inactivated COVID-19 vaccine demonstrated good immunogenicity in PLWH. The protective benefit of booster vaccinations for PLWH cannot be ignored. Implementing a booster vaccination policy for PLWH is an effective approach to providing better protection against the COVID-19 pandemic.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yuting</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xinwei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yunxuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guigang Center for Disease Control and Prevention, Guigang 537100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Rongfeng</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yuexiang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guigang Center for Disease Control and Prevention, Guigang 537100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Wudi</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Fengxiang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Zongxiang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Jinming</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Liufang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Minjuan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Tongxue</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Yinlu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Beibei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Cuixiao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Shanshan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jinmiao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>William J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Li</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-7688-4867</Identifier><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7534-5124</Identifier><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Junjun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4905-9348</Identifier><AffiliationInfo><Affiliation>Guangxi Key Laboratory of AIDS Prevention and Treatment, School of Public Health, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Joint Laboratory for Emerging Infectious Diseases in China (Guangxi)-ASEAN, Life Sciences Institute, Guangxi Medical University, Nanning 530021, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Guike AD21220013</GrantID><Agency>Guangxi Science and Technology Department</Agency><Country /></Grant><Grant><GrantID>YCBZ2022075</GrantID><Agency>Guangxi Medical University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000706269">SARS-CoV-2 inactivated vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="Y">Vaccines, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">PLWH</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword><Keyword MajorTopicYN="N">inactivated COVID-19 vaccine</Keyword></KeywordList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339957</ArticleId><ArticleId IdType="pmc">PMC11437430</ArticleId><ArticleId IdType="doi">10.3390/v16091481</ArticleId><ArticleId IdType="pii">v16091481</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., et al. Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  WHO Coronavirus (COVID-19) Dushboard. 2023.  [(accessed on 12 April 2023)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32661-1</ArticleId><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin J., Zhao Y., Huang F., Yang Y., Huang Y., Zhuang Z., Wang Y., Wang Z., Lin X., Zheng Y., et al. Immune Response and Homeostasis Mechanism Following Administration of BBIBP-CorV SARS-CoV-2 Inactivated Vaccine. Innovation. 2023;4:100359. doi: 10.1016/j.xinn.2022.100359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xinn.2022.100359</ArticleId><ArticleId IdType="pmc">PMC9719934</ArticleId><ArticleId IdType="pubmed">36506806</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan N., Barda N., Kepten E., Miron O., Perchik S., Katz M.A., Hernán M.A., Lipsitch M., Reis B., Balicer R.D. BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting. N. Engl. J. Med. 2021;384:1412–1423. doi: 10.1056/NEJMoa2101765.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2101765</ArticleId><ArticleId IdType="pmc">PMC7944975</ArticleId><ArticleId IdType="pubmed">33626250</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyarsky B.J., Werbel W.A., Avery R.K., Tobian A.A.R., Massie A.B., Segev D.L., Garonzik-Wang J.M. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients. JAMA. 2021;325:2204–2206. doi: 10.1001/jama.2021.7489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.7489</ArticleId><ArticleId IdType="pmc">PMC8100911</ArticleId><ArticleId IdType="pubmed">33950155</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisen U.M., Berner D.K., Tran F., Sümbül M., Vullriede L., Ciripoi M., Reid H.M., Schaffarzyk A., Longardt A.C., Franzenburg J., et al. Immunogenicity and Safety of Anti-SARS-CoV-2 mRNA Vaccines in Patients with Chronic Inflammatory Conditions and Immunosuppressive Therapy in a Monocentric Cohort. Ann. Rheum. Dis. 2021;80:1306–1311. doi: 10.1136/annrheumdis-2021-220272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220272</ArticleId><ArticleId IdType="pmc">PMC8117443</ArticleId><ArticleId IdType="pubmed">33762264</ArticleId></ArticleIdList></Reference><Reference><Citation>Bird S., Panopoulou A., Shea R.L., Tsui M., Saso R., Sud A., West S., Smith K., Barwood J., Kaczmarek E., et al. Response to First Vaccination against SARS-CoV-2 in Patients with Multiple Myeloma. Lancet Haematol. 2021;8:e389–e392. doi: 10.1016/S2352-3026(21)00110-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(21)00110-1</ArticleId><ArticleId IdType="pmc">PMC8055205</ArticleId><ArticleId IdType="pubmed">33887255</ArticleId></ArticleIdList></Reference><Reference><Citation>Monin L., Laing A.G., Muñoz-Ruiz M., McKenzie D.R., Del Molino Del Barrio I., Alaguthurai T., Domingo-Vila C., Hayday T.S., Graham C., Seow J., et al. Safety and Immunogenicity of One Versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients with Cancer: Interim Analysis of a Prospective Observational Study. Lancet Oncol. 2021;22:765–778. doi: 10.1016/S1470-2045(21)00213-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(21)00213-8</ArticleId><ArticleId IdType="pmc">PMC8078907</ArticleId><ArticleId IdType="pubmed">33930323</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W.J., Hu H.Y., Su Q.D., Zhang Z., Liu Y., Sun Y.L., Yang X.D., Sun D.P., Cai S.J., Yang X.X., et al. HIV Prevalence in Suspected Ebola Cases during the 2014-2016 Ebola Epidemic in Sierra Leone. Infect. Dis. Poverty. 2019;8:15. doi: 10.1186/s40249-019-0525-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-019-0525-9</ArticleId><ArticleId IdType="pmc">PMC6398227</ArticleId><ArticleId IdType="pubmed">30827277</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcello A. Latency: The Hidden HIV-1 Challenge. Retrovirology. 2006;3:7. doi: 10.1186/1742-4690-3-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4690-3-7</ArticleId><ArticleId IdType="pmc">PMC1379657</ArticleId><ArticleId IdType="pubmed">16412247</ArticleId></ArticleIdList></Reference><Reference><Citation>UNAIDS  Global HIV &amp; AIDS Statistics—Face Sheet. 2022.  [(accessed on 12 March 2023)].  Available online:  https://www.unaids.org/en/resources/fact-sheet.</Citation></Reference><Reference><Citation>Han M.J. Analysis of the epidemic situation and prospects of HIV/AIDS prevention and control in China. Chin. J. AIDS STD. 2023;29:247–250. doi: 10.13419/j.cnki.aids.2023.03.01.</Citation><ArticleIdList><ArticleId IdType="doi">10.13419/j.cnki.aids.2023.03.01</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiao Y.C., Xu Y., Jiang D.X., Wang X., Wang F., Yang J., Wei Y.S. Epidemiological Analyses of Regional and Age Differences of HIV/AIDS Prevalence in China, 2004–2016. Int. J. Infect. Dis. 2019;81:215–220. doi: 10.1016/j.ijid.2019.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2019.02.016</ArticleId><ArticleId IdType="pubmed">30797071</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasuriar R., Crane H.M., Semeere A.S. Growing Older with HIV in the Treat-All Era. J. Int. AIDS Soc. 2022;25((Suppl. 4)):e25997. doi: 10.1002/jia2.25997.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jia2.25997</ArticleId><ArticleId IdType="pmc">PMC9522984</ArticleId><ArticleId IdType="pubmed">36176021</ArticleId></ArticleIdList></Reference><Reference><Citation>Ssentongo P., Heilbrunn E.S., Ssentongo A.E., Advani S., Chinchilli V.M., Nunez J.J., Du P. Epidemiology and Outcomes of COVID-19 in HIV-Infected Individuals: A Systematic Review and Meta-Analysis. Sci. Rep. 2021;11:6283. doi: 10.1038/s41598-021-85359-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85359-3</ArticleId><ArticleId IdType="pmc">PMC7973415</ArticleId><ArticleId IdType="pubmed">33737527</ArticleId></ArticleIdList></Reference><Reference><Citation>Palich R., Veyri M., Marot S., Vozy A., Gligorov J., Maingon P., Marcelin A.G., Spano J.P. Weak Immunogenicity after a Single Dose of SARS-CoV-2 mRNA Vaccine in Treated Cancer Patients. Ann. Oncol. 2021;32:1051–1053. doi: 10.1016/j.annonc.2021.04.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annonc.2021.04.020</ArticleId><ArticleId IdType="pmc">PMC8081573</ArticleId><ArticleId IdType="pubmed">33932501</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruddy J.A., Connolly C.M., Boyarsky B.J., Werbel W.A., Christopher-Stine L., Garonzik-Wang J., Segev D.L., Paik J.J. High Antibody Response to Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients with Rheumatic and Musculoskeletal Diseases. Ann. Rheum. Dis. 2021;80:1351–1352. doi: 10.1136/annrheumdis-2021-220656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220656</ArticleId><ArticleId IdType="pmc">PMC8843949</ArticleId><ArticleId IdType="pubmed">34031032</ArticleId></ArticleIdList></Reference><Reference><Citation>Milano E., Ricciardi A., Casciaro R., Pallara E., De Vita E., Bavaro D.F., Larocca A.M.V., Stefanizzi P., Tafuri S., Saracino A. Immunogenicity and Safety of the BNT162b2 COVID-19 mRNA Vaccine in PLWH: A Monocentric Study in Bari, Italy. J. Med. Virol. 2022;94:2230–2236. doi: 10.1002/jmv.27629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27629</ArticleId><ArticleId IdType="pmc">PMC9015486</ArticleId><ArticleId IdType="pubmed">35106771</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy I., Wieder-Finesod A., Litchevsky V., Biber A., Indenbaum V., Olmer L., Huppert A., Mor O., Goldstein M., Levin E.G., et al. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in People Living with HIV-1. Clin. Microbiol. Infect. 2021;27:1851–1855. doi: 10.1016/j.cmi.2021.07.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.07.031</ArticleId><ArticleId IdType="pmc">PMC8382485</ArticleId><ArticleId IdType="pubmed">34438069</ArticleId></ArticleIdList></Reference><Reference><Citation>Skowronski D.M., De Serres G. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2021;384:1576–1577. doi: 10.1056/NEJMc2036242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2036242</ArticleId><ArticleId IdType="pubmed">33596348</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi S.A., Koen A.L., Izu A., Fairlie L., Cutland C.L., Baillie V., Padayachee S.D., Dheda K., Barnabas S.L., Bhorat Q.E., et al. Safety and Immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in People Living with and without HIV in South Africa: An Interim Analysis of a Randomised, Double-Blind, Placebo-Controlled, Phase 1B/2A Trial. Lancet HIV. 2021;8:e568–e580. doi: 10.1016/S2352-3018(21)00157-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(21)00157-0</ArticleId><ArticleId IdType="pmc">PMC8372504</ArticleId><ArticleId IdType="pubmed">34416193</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y., Zhang Y., He Z., Huang H., Tian X., Wang G., Chen D., Ren Y., Jia L., Wang W., et al. Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in People Living with HIV-1: A Non-Randomized Cohort Study. EClinicalMedicine. 2022;43:101226. doi: 10.1016/j.eclinm.2021.101226.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101226</ArticleId><ArticleId IdType="pmc">PMC8642727</ArticleId><ArticleId IdType="pubmed">34901799</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Han J., Li X., Chen D., Zhao X., Qiu Y., Zhang L., Xiao J., Li B., Zhao H. COVID-19 Vaccination in People Living with HIV (Plwh) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity. Vaccines. 2021;9:1458. doi: 10.3390/vaccines9121458.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9121458</ArticleId><ArticleId IdType="pmc">PMC8706383</ArticleId><ArticleId IdType="pubmed">34960204</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei S.C., Hsu W.T., Chiu C.H., Chang F.Y., Lo H.R., Liao C.Y., Yang H.I., Chou Y.C., Tsai C.H., Chao Y.C. An Integrated Platform for Serological Detection and Vaccination of COVID-19. Front. Immunol. 2021;12:771011. doi: 10.3389/fimmu.2021.771011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.771011</ArticleId><ArticleId IdType="pmc">PMC8734241</ArticleId><ArticleId IdType="pubmed">35003088</ArticleId></ArticleIdList></Reference><Reference><Citation>Asashima H., Mohanty S., Comi M., Ruff W.E., Hoehn K.B., Wong P., Klein J., Lucas C., Cohen I., Coffey S., et al. PD-1(High)CXCR5(-)CD4(+) Peripheral Helper T Cells Promote CXCR3(+) Plasmablasts in Human Acute Viral Infection. Cell Rep. 2023;42:111895. doi: 10.1016/j.celrep.2022.111895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2022.111895</ArticleId><ArticleId IdType="pmc">PMC9806868</ArticleId><ArticleId IdType="pubmed">36596303</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y.C., Tsai C.H., Wang Y.C., Yen L.C., Chang Y.W., Sun J.R., Lin T.Y., Chiu C.H., Chao Y.C., Chang F.Y. SARS-CoV-2 Nucleocapsid Protein, Rather than Spike Protein, Triggers a Cytokine Storm Originating from Lung Epithelial Cells in Patients with COVID-19. Infection. 2023;52:955–983. doi: 10.1007/s15010-023-02142-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02142-4</ArticleId><ArticleId IdType="pmc">PMC11143065</ArticleId><ArticleId IdType="pubmed">38133713</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO  COVID-19 Vaccine Tracker and Landscape. 2023.  [(accessed on 30 March 2023)].  Available online:  https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.</Citation></Reference><Reference><Citation>Zhang Y., Zeng G., Pan H., Li C., Hu Y., Chu K., Han W., Chen Z., Tang R., Yin W., et al. Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18–59 Years: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial. Lancet Infect. Dis. 2021;21:181–192. doi: 10.1016/S1473-3099(20)30843-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30843-4</ArticleId><ArticleId IdType="pmc">PMC7832443</ArticleId><ArticleId IdType="pubmed">33217362</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S., Zhang Y., Wang Y., Wang H., Yang Y., Gao G.F., Tan W., Wu G., Xu M., Lou Z., et al. Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBIBP-CorV: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Trial. Lancet Infect. Dis. 2021;21:39–51. doi: 10.1016/S1473-3099(20)30831-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30831-8</ArticleId><ArticleId IdType="pmc">PMC7561304</ArticleId><ArticleId IdType="pubmed">33069281</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao G.F., Liu W.J. Let’s Get Vaccinated for Both Flu and COVID-19: On the World Flu Day 2021. China CDC Wkly. 2021;3:915–917. doi: 10.46234/ccdcw2021.227.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2021.227</ArticleId><ArticleId IdType="pmc">PMC8563337</ArticleId><ArticleId IdType="pubmed">34745691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kernéis S., Launay O., Turbelin C., Batteux F., Hanslik T., Boëlle P.Y. Long-Term Immune Responses to Vaccination in Hiv-Infected Patients: A Systematic Review and Meta-Analysis. Clin. Infect. Dis. 2014;58:1130–1139. doi: 10.1093/cid/cit937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/cit937</ArticleId><ArticleId IdType="pmc">PMC4761378</ArticleId><ArticleId IdType="pubmed">24415637</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogbe A., Pace M., Bittaye M., Tipoe T., Adele S., Alagaratnam J., Aley P.K., Ansari M.A., Bara A., Broadhead S., et al. Durability of ChAdOx1 nCoV-19 Vaccination in People Living with HIV. JCI Insight. 2022;7:e157031. doi: 10.1172/jci.insight.157031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.157031</ArticleId><ArticleId IdType="pmc">PMC9057612</ArticleId><ArticleId IdType="pubmed">35192543</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng G., Wu Q., Pan H., Li M., Yang J., Wang L., Wu Z., Jiang D., Deng X., Chu K., et al. Immunogenicity and Safety of a Third Dose of CoronaVac, and Immune Persistence of a Two-Dose Schedule, in Healthy Adults: Interim Results from Two Single-Centre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Clinical Trials. Lancet Infect. Dis. 2022;22:483–495. doi: 10.1016/S1473-3099(21)00681-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00681-2</ArticleId><ArticleId IdType="pmc">PMC8651254</ArticleId><ArticleId IdType="pubmed">34890537</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., Grifoni A., Ramirez S.I., Haupt S., Frazier A., et al. Immunological Memory to SARS-CoV-2 Assessed for up to 8 Months after Infection. Science. 2021;371:eabf4063. doi: 10.1126/science.abf4063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Lin H., Ye B., Zhao M., Zhan J., Dong S., Guo Y., Zhao Y., Li M., Liu S., et al. One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents. Clin. Infect. Dis. 2022;75:e1072–e1081. doi: 10.1093/cid/ciab884.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab884</ArticleId><ArticleId IdType="pmc">PMC8524303</ArticleId><ArticleId IdType="pubmed">34609506</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R.R., Apostolidis S.A., Painter M.M., Mathew D., Pattekar A., Kuthuru O., Gouma S., Hicks P., Meng W., Rosenfeld A.M., et al. Distinct Antibody and Memory B Cell Responses in SARS-CoV-2 Naïve and Recovered Individuals following mRNA Vaccination. Sci. Immunol. 2021;6:eabi6950. doi: 10.1126/sciimmunol.abi6950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abi6950</ArticleId><ArticleId IdType="pmc">PMC8158969</ArticleId><ArticleId IdType="pubmed">33858945</ArticleId></ArticleIdList></Reference><Reference><Citation>George V.K., Pallikkuth S., Parmigiani A., Alcaide M., Fischl M., Arheart K.L., Pahwa S. HIV Infection Worsens Age-Associated Defects in Antibody Responses to Influenza Vaccine. J. Infect. Dis. 2015;211:1959–1968. doi: 10.1093/infdis/jiu840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiu840</ArticleId><ArticleId IdType="pmc">PMC4836723</ArticleId><ArticleId IdType="pubmed">25556252</ArticleId></ArticleIdList></Reference><Reference><Citation>Avelino-Silva V.I., Miyaji K.T., Hunt P.W., Huang Y., Simoes M., Lima S.B., Freire M.S., Caiaffa-Filho H.H., Hong M.A., Costa D.A., et al. CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients. PLoS Negl. Trop. Dis. 2016;10:e0005219. doi: 10.1371/journal.pntd.0005219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0005219</ArticleId><ArticleId IdType="pmc">PMC5179051</ArticleId><ArticleId IdType="pubmed">27941965</ArticleId></ArticleIdList></Reference><Reference><Citation>Frater J., Ewer K.J., Ogbe A., Pace M., Adele S., Adland E., Alagaratnam J., Aley P.K., Ali M., Ansari M.A., et al. Safety and Immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) Vaccine against SARS-CoV-2 in HIV Infection: A Single-Arm Substudy of a Phase 2/3 Clinical Trial. Lancet HIV. 2021;8:e474–e485. doi: 10.1016/S2352-3018(21)00103-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(21)00103-X</ArticleId><ArticleId IdType="pmc">PMC8213361</ArticleId><ArticleId IdType="pubmed">34153264</ArticleId></ArticleIdList></Reference><Reference><Citation>Müller L., Andrée M., Moskorz W., Drexler I., Walotka L., Grothmann R., Ptok J., Hillebrandt J., Ritchie A., Rabl D., et al. Age-dependent Immune Response to the Biontech/Pfizer BNT162b2 Coronavirus Disease 2019 Vaccination. Clin. Infect. Dis. 2021;73:2065–2072. doi: 10.1093/cid/ciab381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab381</ArticleId><ArticleId IdType="pmc">PMC8135422</ArticleId><ArticleId IdType="pubmed">33906236</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro J.R., Sitaras I., Park H.S., Aytenfisu T.Y., Caputo C., Li M., Lee J., Johnston T.S., Li H., Wouters C., et al. Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine-Induced Immunity in Older Adults. Clin. Infect. Dis. 2022;75:S61–S71. doi: 10.1093/cid/ciac397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac397</ArticleId><ArticleId IdType="pmc">PMC9376280</ArticleId><ArticleId IdType="pubmed">35607747</ArticleId></ArticleIdList></Reference><Reference><Citation>Soto-Nava M., Dávila-Conn V., Venancio-Rocha J.P., García-Esparza P., Tapia-Trejo D., Hernández-Juan R., Zarza-Sánchez E., Murakami-Ogasawara A., Ávila-Ríos S. SARSCoV-2 Antibody Prevalence and Titers in Persons Living with HIV Cared for at a Large Tertiary Reference Center in Mexico City. Virol. J. 2023;20:300. doi: 10.1186/s12985-023-02261-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-02261-2</ArticleId><ArticleId IdType="pmc">PMC10724955</ArticleId><ArticleId IdType="pubmed">38102622</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B., Shilo S., Rossman H., Kalkstein N., Marcus K., Barer Y., Keshet A., Shamir-Stein N., Shalev V., Zohar A.E., et al. Longitudinal Symptom Dynamics of COVID-19 Infection. Nat. Commun. 2020;11:6208. doi: 10.1038/s41467-020-20053-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20053-y</ArticleId><ArticleId IdType="pmc">PMC7718370</ArticleId><ArticleId IdType="pubmed">33277494</ArticleId></ArticleIdList></Reference><Reference><Citation>Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin. Infect. Dis. 2021;73:e2005–e2015. doi: 10.1093/cid/ciaa1198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1198</ArticleId><ArticleId IdType="pmc">PMC7499501</ArticleId><ArticleId IdType="pubmed">32860699</ArticleId></ArticleIdList></Reference><Reference><Citation>José Luis Santiago B., Jesús C., José Ramón B., Julián O., Lazzari E.L.D., Leire B., Jesús T., Hugo H.K., Sanza-Moreno J., Alicia Hernández G., et al.  A Prospective Case-Cohort Study of COVID-19 in Persons with Hiv: COVIH-19 Study. Top. Antivir. Med. 2021.  [(accessed on 30 March 2023)].  Available online:  https://www.croiconference.org/abstract/a-prospective-case-cohort-study-of-covid-19-in-persons-with-hiv-covih-19-study/</Citation></Reference><Reference><Citation>Inciarte A., Gonzalez-Cordon A., Rojas J., Torres B., de Lazzari E., de la Mora L., Martinez-Rebollar M., Laguno M., Callau P., Gonzalez-Navarro A., et al. Clinical Characteristics, Risk Factors, and Incidence of Symptomatic Coronavirus Disease 2019 in a Large Cohort of Adults Living with HIV: A Single-Center, Prospective Observational Study. AIDS. 2020;34:1775–1780. doi: 10.1097/QAD.0000000000002643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000002643</ArticleId><ArticleId IdType="pmc">PMC7493771</ArticleId><ArticleId IdType="pubmed">32773471</ArticleId></ArticleIdList></Reference><Reference><Citation>Fatima S., Zafar A., Afzal H., Ejaz T., Shamim S., Saleemi S., Subhan Butt A. COVID-19 Infection among Vaccinated and Unvaccinated: Does It Make any Difference? PLoS ONE. 2022;17:e0270485. doi: 10.1371/journal.pone.0270485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0270485</ArticleId><ArticleId IdType="pmc">PMC9286242</ArticleId><ArticleId IdType="pubmed">35839210</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>